By diverging from the common path of the volume- and product-driven drug development and discovery process, the company believes it can better serve customers and patients alike. This organizational and cultural shift is ahead of the curve, particularly as key trends like personalized medicine and patient demand for transparency continue to influence the pharmaceutical supply chain. To catalyze this change, Piramal Pharma Solutions (PPS) has taken meaningful steps to make patient centricity fundamental to its corporate structure and mindset. By shifting its focus from products to patients, PPS is seeking to enhance patient lives while strengthening customer relationships. “Patient centricity is about more than running a business,” said Peter DeYoung, CEO of Piramal Global Pharma. “It’s a circular relationship between the CDMO [contract development and manufacturing organization], pharma sponsor, and patient. As an industry, we must recognize and take ownership of our responsibility to patients.” Read the whitepaper to know more.
